ROCKVILLE, Md., Dec. 4, 2007 (PRIME NEWSWIRE) -- Cytomedix, Inc. (AMEX:GTF - News) today announced that it has filed a registration statement on Form S-3 with the Securities and Exchange Commission (SEC) which, when declared effective by the SEC, will cover the resale by certain selling shareholders of up to 2,940,665 shares of common stock, of which 1,300,000 are shares of common stock that are issuable as of Nov. 30, 2007, and 1,640,665 are shares of common stock that, as of Nov. 30, 2007, are issuable to certain shareholders upon exercise of outstanding warrants. The 2,940,655 shares of common stock that may be sold by selling shareholders include 1.3 million shares of common stock and warrants to purchase an additional 975,000 shares of common stock that were issued to the Company's patent counsel as a payment of current and future contingency fees under a prior retainer agreement.
